We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Critical Care

Optimizing Acid-Base Stability in CVVH: Why Lower Bicarbonate Fluids Outperform Standard Concentrations During Regional Citrate Anticoagulation

MedXY Editorial Team•Dec 26, 2025•Critical Care
CRRTNephrology

Highlights

  • Lower bicarbonate replacement fluid (LBF, 22 mmol/l) significantly reduces the risk of pH and bicarbonate excursions compared to high bicarbonate fluid (HBF, 30 mmol/l) during CVVH.
  • The use of HBF was associated with a 3.6-fold increased risk of bicarbonate levels falling outside the standard range.
  • Importantly, the time to normalize pH in acidotic patients was not delayed by using the lower bicarbonate concentration.
  • Regional citrate anticoagulation (RCA) acts as a significant endogenous source of bicarbonate, necessitating a reduction in exogenous bicarbonate to prevent metabolic overcorrection.

Introduction: The Challenge of Acid-Base Homeostasis in CRRT

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Thyroid Hormones May Offer a New Therapeutic and Prognostic Angle in ADPKDThyroid hormone signaling may influence ADPKD progression, with preclinical cyst suppression and patient biomarker associations suggesting prognostic and therapeutic potential.Jun 19, 2026Renal Function and Metabolic Risk: Reduced eGFR Does Not Independently Increase DKA Risk in Type 1 DiabetesA landmark 35-year analysis of DCCT/EDIC data demonstrates that a reduced estimated glomerular filtration rate (30–90 mL/min/1.73 m2) is not an independent risk factor for diabetic ketoacidosis, providing a clearer safety framework for the Mar 7, 2026Selective TRPC6 Inhibition Emerges as a Novel Therapeutic Paradigm for Focal Segmental GlomerulosclerosisA Phase 2 trial of BI 764198, a selective TRPC6 inhibitor, demonstrates significant proteinuria reduction in patients with focal segmental glomerulosclerosis. This study provides the first clinical evidence for podocyte-targeted therapy, maFeb 15, 2026Liberating the Kidney: Can a Conservative Dialysis Strategy Improve Recovery in AKI-D?The LIBERATE-D randomized trial suggests that a conservative, indication-driven dialysis strategy may enhance kidney recovery and reduce treatment burden in stable patients with dialysis-requiring acute kidney injury compared to conventiona
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Feb 9, 2026
Beyond the Dialyzer: The Multidimensional Burden of Chronic Pain in Maintenance Hemodialysis PatientsA cross-sectional analysis of the HOPE Consortium Trial reveals that chronic pain in hemodialysis patients is widespread, frequently musculoskeletal and neuropathic, and strongly associated with psychological and sociodemographic factors raFeb 3, 2026
SGLT2 Inhibitors Edge Out GLP-1 RAs in Kidney Protection: Insights from a Target Trial EmulationA nationwide Danish study suggests SGLT2 inhibitors offer superior protection against chronic kidney disease and acute kidney injury compared to GLP-1 receptor agonists in patients with type 2 diabetes, particularly for primary prevention.Jan 26, 2026